Search for drugs:
Typing the drug name to query
DIMETHYL FUMARATE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Potential to Prolong the QT Interval
- In a placebo-controlled thorough QT study performed in healthy subjects, there was no evidence that dimethyl fumarate caused QT interval prolongation of clinical significance (i.e., the upper bound of the 90% confidence interval for the largest placebo-adjusted, baseline-corrected QTc was below 10 ms).
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
5
24087
Other ADRs
257839
38123748
Odds Ratio = 0.031
Drug Property Information
ATC Code(s):
- L04AX07 - dimethyl fumarate
- L04AX - Other immunosuppressants
- L04A - IMMUNOSUPPRESSANTS
- L04 - IMMUNOSUPPRESSANTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Active Ingredient:DIMETHYL FUMARATE
Active Ingredient UNII:FO2303MNI2
Drugbank ID:DB08908
PubChem Compound:637568
PharmGKB:PA166152838
CAS Number:624-49-7
Dosage Form(s):capsule, delayed release
Route(s) Of Administrator:oral
Daily Dose:
- 480.0 mg/day L04AX07
Chemical Structure: 
SMILE Code:
[H]\C(=C(\[H])C(=O)OC)C(=O)OC
[H]\C(=C(\[H])C(=O)OC)C(=O)OC
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.